Zacks Research Has Positive Outlook of Prothena Q1 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Prothena in a research report issued on Wednesday, March 12th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings per share of ($1.06) for the quarter, up from their previous forecast of ($1.33). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.

Other equities analysts have also recently issued research reports about the stock. Bank of America dropped their price target on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Royal Bank of Canada dropped their target price on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a research report on Friday, February 21st. Finally, Oppenheimer lifted their target price on shares of Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Prothena currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Stock Performance

Shares of NASDAQ PRTA opened at $12.83 on Monday. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $26.45. The stock has a market cap of $690.60 million, a price-to-earnings ratio of -5.58 and a beta of -0.02. The firm’s 50-day simple moving average is $14.38 and its 200 day simple moving average is $15.98.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million.

Institutional Investors Weigh In On Prothena

A number of hedge funds have recently modified their holdings of PRTA. Virtus ETF Advisers LLC grew its stake in Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 833 shares in the last quarter. Headlands Technologies LLC grew its stake in Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Prothena in the 4th quarter valued at approximately $145,000. Purkiss Capital Advisors LLC purchased a new position in Prothena in the 4th quarter valued at approximately $149,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,065 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.